respiratory syncyti virus rev lead caps mediator viral tract infect neither vaccine effect antivirus therapy avail prevent treat infect palivizumab human monoclonal antibody product approve serious high cost prohibit lowincom country aim identify safe afford agent preexposur prophylaxi prep child risk found male anhydride mlmodifi human serum album sha design mls exhibit potent active percentage modify lysine margin ml correct antics inhibit entry replica interact g protein block attach target cell mla bound f proteinmedi membrane fusion entrants administer result signifies decrease tier lung mouse show promise develop easytous regimen low highincom 